Brain radiotherapy in patients treated for a newly diagnosed primary central nervous system lymphoma: professional practice evaluation in 19 French centers

Authors

  • Alice Thomas-Joulié a Department of Radiation Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France; b Department of Radiation Oncology, Hôpitaux Universitaires La Pitié Salpêtrière – Charles Foix, APHP, Paris, France
  • Caroline Houillier c Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Paris, France
  • Delphine Antoni a Department of Radiation Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
  • Gilles Créhange d Department of Radiation Oncology, Institut Curie, PSL Research University, Paris, France; e Department of Radiation Oncology, Institut de cancérologie de l‘Ouest, Nantes-Saint-Herblain, France
  • Emmanuel Jouglar d Department of Radiation Oncology, Institut Curie, PSL Research University, Paris, France; e Department of Radiation Oncology, Institut de cancérologie de l‘Ouest, Nantes-Saint-Herblain, France
  • Philippe Colin f Department of Radiation Oncology, Institut du Cancer Courlancy, Rouen, France
  • Mohamed Benchalal g Department of Radiation Oncology, Centre Eugène Marquis, Rennes, Bretagne, France
  • Philippe Lang h Federation Universitaire d‘oncologie radiothérapie d‘Occitanie, ICG CHU Caremeau, Nîmes, France
  • Marc Alfonsi i Institut Sainte Catherine, Avignon, France
  • Hadji Hamidou j Department of Radiation Oncology, ICO Cancer Center, Centre Paul Papin, Angers, France
  • Alexandre Coutte k Department of Radiation Oncology, Centre Hospitalier Universitaire d’Amiens, Amiens, France
  • Flora Ahrweiller l Institut de cancérologie et radiothérapie bretillien, Saint Malo, France
  • Nathalie Dadoun m Department of Radiation Oncology, Centre de la Baie, Avranches, France
  • Yohan Pointreau n Department of Radiation Oncology, Centre Jean Bernard, Le Mans, France
  • Hanifa Ammarguellat o Department of Radiation Oncology, Centre Hospitalier Simone Veil, Beauvais, France
  • Valérie Bernier-Chastagner p Department of Radiation Oncology, Institut de Cancérologie de Lorraine, Nancy, France
  • Yazid Belkacemi q Department of Radiation Oncology, Hôpital Universitaire Henri Mondor, Créteil, France
  • Sabine Vieillot r Department of Radiation Oncology, Centre Catalan d’Oncologie, Perpignan, France
  • Khê Hoang-Xuan c Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Paris, France
  • Carole Soussain s Department of Hematology, Institut Curie site de Saint-Cloud, Paris, France;t INSERM U932 Institut Curie, PSL Research University, Paris, France
  • Julian Jacob b Department of Radiation Oncology, Hôpitaux Universitaires La Pitié Salpêtrière – Charles Foix, APHP, Paris, France
  • Loïc Feuvret b Department of Radiation Oncology, Hôpitaux Universitaires La Pitié Salpêtrière – Charles Foix, APHP, Paris, France; u Department of Radiation Oncology, Centre Hospitalier Universitaire Lyon Sud, Lyon, France

DOI:

https://doi.org/10.1080/0284186X.2023.2225146

Keywords:

Radiotherapy, primary central nervous system lymphoma, consolidation therapy, first-line therapy, recommendations

Abstract

Introduction

The objective of this study was a multicentric evaluation of professional practices, analyzing the irradiation technique itself and its impact on survival and recurrence sites, in primary central nervous system lymphomas (PCNSLs).

Methods

We retrospectively analyzed the technical and clinical records of 79 PCNSL patients included in the database of the national expert network for oculocerebral lymphoma (‘LOC’) who were treated with brain radiotherapy as first-line treatment for newly diagnosed primary central nervous system lymphoma between 2011 and 2018.

Results

The number of patients treated with brain radiotherapy gradually decreased over time. The heterogeneity of radiotherapy prescriptions was significant, and 55% of them did not comply with published recommendations in terms of irradiation dose and/or volume. The proportion of complete responders to induction chemotherapy treated with reduced-dose radiotherapy increased over time. Partial brain radiotherapy was associated with significantly lower overall survival in univariate analysis. In partial responders to induction chemotherapy, increasing the total dose to the brain >30 Gy and adding a boost to the WBRT induced a trend toward improved progression-free and overall survival. Five recurrences (13%) occurred exclusively in the eyes, all in patients whose eyes had been excluded from the irradiation target volume and including 2 patients without ocular involvement at diagnosis.

Conclusion

The visibility of recommendations for prescribing brain radiotherapy for the treatment of newly diagnosed primary central nervous system lymphoma needs to be improved to harmonize practices and improve their quality. We propose an update of the recommendations.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2023-06-03

How to Cite

Thomas-Joulié, A., Houillier, C., Antoni, D., Créhange, G., Jouglar, E., Colin, P., … Feuvret, L. (2023). Brain radiotherapy in patients treated for a newly diagnosed primary central nervous system lymphoma: professional practice evaluation in 19 French centers. Acta Oncologica, 62(6), 648–656. https://doi.org/10.1080/0284186X.2023.2225146